Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus-Reference-Cited by-同舟云学术

Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus

Published:2010-04 Issue:4 Volume:21 Page:439-450
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Galivo Feorillo¹,Diaz Rosa Maria¹²,Thanarajasingam Uma³,Jevremovic Dragan⁴,Wongthida Phonphimon¹,Thompson Jill¹,Kottke Timothy¹,Barber Glen N.⁵,Melcher Alan⁶,Vile Richard G.¹²⁶

Affiliation:

1. Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905.

2. Department of Immunology, Mayo Clinic, Rochester, MN 55905.

3. Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905.

4. Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905.

5. Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136.

6. Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.2009.143

Reference34 articles.

1. Defective translational control facilitates vesicular stomatitis virus oncolysis

2. Oncolytic Activity of Vesicular Stomatitis Virus Is Effective against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of Apoptosis

3. The CD40 Antigen and its Ligand

4. VSV-tumor selective replication and protein translation

5. Getting oncolytic virus therapies off the ground

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy;International Journal of Molecular Sciences;2024-04-25

2. Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth;Vaccines;2024-03-21

3. Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations;Biomedicines;2022-08-31

4. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells;Human Gene Therapy;2022-06-01

5. Improving immunovirotherapies: the intersection of mathematical modelling and experiments;ImmunoInformatics;2022-06